mRNA COVID vaccines pull ahead, and I have a favorite
Investment gaps in cancer biotech (and why you should bet on Texas)
Bispecific therapeutics are about to make a big comeback
Better, faster, cheaper drug development is here to stay
How Moderna is winning the race to a COVID-19 vaccine